Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialYukio Kondo, Fredrik Schjesvold, Albert Oriol et al.|The Lancet Haematology|2019Cited by 247
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trialGabriela Gonzalez, A. Lage, Yanela Santiesteban González et al.|Annals of Oncology|1998Cited by 155
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 studyJohn Kuruvilla, Nancy L. Bartlett, Philippe Armand et al.|Leukemia & lymphoma/Leukemia and lymphoma|2022Cited by 28